EXECUTIVE TERMINATION AGREEMENT AND GENERAL RELEASE
This EXECUTIVE TERMINATION AGREEMENT AND GENERAL RELEASE (“Executive Termination Agreement” or
“Agreement”) is entered into between Alan Fuhrman (“Executive”) and Sonus Pharmaceuticals, Inc. (to be renamed
“OncoGenex Pharmaceuticals, Inc.”) (referred to herein as “Sonus” or “Employer”).
WHEREAS, both parties to this Agreement wish to clearly set forth the terms of Executive’s termination for “Good
Reason” from employment with Employer.
Now, THEREFORE, in exchange for the severance pay and other benefits described in this Agreement, Executive and
Employer agree as follows:
1. As a result of the restructuring of Employer’s operations, Executive’s employment with Employer shall terminate
effective as of the date set out in the written notice from Sonus to Executive (“Termination Date”), which notice is attached
hereto as Exhibit A, and be deemed a termination for “Good Reason.”
2. Executive represents and agrees that, with the exception of the compensation and benefits to be provided to
Executive pursuant to the terms of the January 11, 2008 Letter Agreement signed by Executive and Sonus, a copy of which is
attached hereto as Exhibit B (“January 2008 Severance Agreement”), he has received all compensation owed to him by Employer
through his Termination Date, including any and all wages, bonuses, commissions, earned but unused vacation, reimbursable
business expenses, incentives, stock options, and any other payments, benefits, or other compensation of any kind to which he
was entitled from Employer.
3. In reliance on Executive’s promises, representations, and releases in this Agreement, after Employer’s receipt of
this executed Executive Termination Agreement and provided that Executive does not revoke this Agreement pursuant to
Paragraph 7, Employer will provide to Executive all compensation and benefits set out in the January 2008 Severance
Agreement. A severance payout of $255,900.00, plus accru